Journal of Clinical Oncology

Vol. 44, Issue 16_suppl Issue 16_suppl 2026
7213
Articles

Articles in this Issue

Patient-reported outcomes from the adjuvant ado-trastuzumab emtansine (T-DM1) for older patients with HER2+ breast cancer (ATOP) trial.

Kathryn Jean Ruddy, Brenda F. Ginos, Hillary Heiling et al. Jun 01, 2026 pp. 635-635 10.1200/jco.2026.44.16_suppl.635

635 Background: Prospective data on efficacy, quality of life, and treatment-related toxicities in older adults with breas...

Effect of ripretinib on the pharmacokinetics (PK) of midazolam (MDZ), a sensitive CYP3A probe substrate, in adult patients (pts) with advanced gastrointestinal stromal tumor (GIST).

Lakshmi Viswanathan, Paige Daniel, Soumya Balachandran et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23509

e23509 Background: Ripretinib is a switch-control tyrosine kinase inhibitor (TKI) indicated for the treatment of adult pts...

Real-world treatment patterns and overall survival (OS) in patients (pts) with HER2-positive (HER2+) advanced or metastatic gastroesophageal adenocarcinomas (mGEA) in the US.

Farshid Dayyani, Xiaozhou Fan, Joan Zape et al. Jun 01, 2026 pp. 4053-4053 10.1200/jco.2026.44.16_suppl.4053

4053 Background: The first-line (1L) standard of care for pts with HER2+ mGEA is HER2-targeted therapy (HER2 Tx) plus plat...

Pirtobrutinib in treatment-naïve patients with CLL/SLL: Pooled results from BRUIN CLL-313 and BRUIN CLL-314.

William G. Wierda, Wojciech Jurczak, Jose Antonio Garcia Vela et al. Jun 01, 2026 pp. 7044-7044 10.1200/jco.2026.44.16_suppl.7044

7044 Background: Pirtobrutinib, a highly selective, non-covalent Bruton tyrosine kinase inhibitor (BTKi), is approved glob...

The efficacy and safety of add-on ruxolitinib for patients with severe checkpoint inhibitor pneumonitis management with corticosteroids: A multicenter, open-label, randomised phase 2 trial.

Yan Xu, Xiaoxing Gao, Chen Wei et al. Jun 01, 2026 pp. 12016-12016 10.1200/jco.2026.44.16_suppl.12016

12016 Background: Checkpoint inhibitor pneumonitis (CIP) stands out as a remarkable complication during ICIs therapy. Seve...

Association of proton pump inhibitor use with cancer-specific mortality in a nationally representative U.S. cohort (NHANES, 1999–2018).

Albine Djeagou F., George Davidson, Shubhangi Sharma et al. Jun 01, 2026 pp. 10625-10625 10.1200/jco.2026.44.16_suppl.10625

10625 Background: Proton pump inhibitors (PPIs) are widely used and often continued beyond recommended durations. Evidence...

Predictors of EGFR-mutant primary lung adenocarcinoma.

Lauren Kriger Groner, Eunji Choi, Luchang Cui et al. Jun 01, 2026 pp. 10591-10591 10.1200/jco.2026.44.16_suppl.10591

10591 Background: The proportion of lung cancer cases in individuals who have never smoked (INS) is increasing. Most of th...

Inpatient outcomes by socioeconomic characteristics among younger adults hospitalized with gastrointestinal malignancies in the United States, 2018–2022.

Emaan Tiwana, Daniel Thomas Jones, Emi Hearn et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23168

e23168 Background: Early-onset gastrointestinal (GI) cancers are increasingly recognized, yet national data describing inp...

Association of acute myeloid leukemia (AML) patient, disease, and molecular characteristics with a long-term (LT) response to olutasidenib.

Justin M. Watts, Brian Andrew Jonas, Arnaud Pigneux et al. Jun 01, 2026 pp. 6523-6523 10.1200/jco.2026.44.16_suppl.6523

6523 Background: Mutations in isocitrate dehydrogenase 1 (m IDH1 ) occur in 7%-14%...

Comparative risk of osteopenia, osteoporosis, and pathological fractures in breast cancer patients treated with steroidal versus non-steroidal aromatase inhibitors: A large-scale real-world data analysis.

Alexander Urena, Gokul Karthikeyan, Feras Al Moussally et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e12683

e12683 Background: Aromatase inhibitors (AIs) are widely used in hormone positive breast cancer. They are classified as ei...

Real-world outcomes of atezolizumab versus durvalumab in extensive-stage small cell lung cancer.

Elsy Rivera, Kevin Zhu, Haley Moriarty et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23393

e23393 Background: Advent landmark trials, IMpower133 and CASPIAN, demonstrated improved median progression-free survival...

Disparities in statin prescription for secondary prevention of atherosclerotic cardiovascular disease in a Midwestern lung cancer screening population.

Akila Anandarajah, Rida Qureshi, Lindsey M. Filiatreau et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13723

e13723 Background: Heart issues are a leading cause of death among lung cancer patients. Statins can effectively reduce pa...

A phase 1, first-in-human study of DS5361, a small-molecule, nonsense-mediated mRNA decay (NMD) inhibitor in patients with advanced/metastatic solid tumors (parts 1 and 2).

Shiraj Sen, Benedito A. Carneiro, Judy S. Wang et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps2680

TPS2680 Background: Despite the profound impact of immune checkpoint inhibitors (ICIs) on the treatment of patients with a...

A global phase 1/2a trial of SHR-A1904, a CLDN18.2-targeting ADC, in advanced solid tumors expressing CLDN18.2.

Min-Hee Ryu, Charlotte Rose Lemech, Vinod Ganju et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15018

e15018 Background: SHR-A1904, a novel CLDN18.2 targeted ADC, showed promising antitumor activity in pretreated CLDN18.2-po...

Integrated proteogenomic profiling to reveal prognostic subtypes and actionable targets in adenoid cystic carcinoma.

Jiawei Zhou, Peiwen Ma, Bingnan Wang et al. Jun 01, 2026 pp. 6067-6067 10.1200/jco.2026.44.16_suppl.6067

6067 Background: Adenoid cystic carcinoma (ACC) is a rare head and neck malignancy characterized by highly variable clinic...

Genetic signatures of CNS relapse in DLBCL patients profiled with next-generation sequencing (NGS).

Jackson Thomas Bowers, Anjanaa Vijayanarayanan, Natalie Gill et al. Jun 01, 2026 pp. 7016-7016 10.1200/jco.2026.44.16_suppl.7016

7016 Background: CNS relapse of DLBCL is a devastating event with median survival <6 months. While the overall incidenc...

Clinicopathologic features of South African colorectal cancer patients by HIV status in a retrospective cohort study.

Jacob Lee Dubner, Madhav Nekkar, Alexander Morris et al. Jun 01, 2026 pp. 3658-3658 10.1200/jco.2026.44.16_suppl.3658

3658 Background: Colorectal cancer (CRC) is increasing among people living with HIV. South Africa (SA) has the largest HIV...

Targeting MAT2A-mediated metabolic pathways: A novel strategy for non-small cell lung cancer therapy.

Qiyu Fang, Qian Liu, Yimin Chen et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20711

e20711 Background: Methionine adenosyltransferase 2A (MAT2A) links metabolic reprogramming with epigenetic regulation by p...

Cardiotoxicity and mortality trends in chemotherapy-treated breast cancer patients before and during the COVID-19 pandemic.

Bhumi B. Bhakta, Aileen Baecker, Erika Libiar Estrada et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e24013

e24013 Background: The Coronavirus Disease 2019 (COVID-19) pandemic caused widespread disruptions in breast cancer screeni...

Registry-based machine learning in Sezary syndrome: Assessment of prognostic signal and age-masked racial inequities.

Tiantian Zhang, Simo Du, Zhe Wang et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e22615

e22615 Background: Sézary syndrome (SS) is a rare leukemic cutaneous T-cell lymphoma with limited contemporary population...

Impact of COVID-19 mRNA vaccines on survival outcomes in patients with solid tumors receiving immunotherapy: A large-scale retrospective study.

Bayan Khasawneh, Mostafa Eysha, Rafik ElBeblawy et al. Jun 01, 2026 pp. 2637-2637 10.1200/jco.2026.44.16_suppl.2637

2637 Background: Immune checkpoint inhibitors (ICIs) became the cornerstone in the treatment of solid tumors. While person...

Phase II single-arm trial of low-dose capecitabine in patients with advanced breast cancer.

Humaira Sarfraz, Vinod Kumar, Mauricio Ramiro Escobar et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps1159

TPS1159 Background: Capecitabine is approved for use in both the adjuvant and metastatic settings of breast cancer. The cl...

A network analysis of symptoms in women with metastatic breast cancer undergoing systemic therapy.

Yan Zhan, M. Tish Knobf, Liang Shan et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13107

e13107 Background: Women with metastatic breast cancer (MBC) experience various concurrent symptoms during cancer treatmen...

Updated efficacy results from the phase I cervical cancer cohort of BAT8008, a TROP-2–directed antibody-drug conjugate, in patients with advanced cervical cancer.

Jianli Zhao, Wenjuan Chen, Mingjun Zhang et al. Jun 01, 2026 pp. 5507-5507 10.1200/jco.2026.44.16_suppl.5507

5507 Background: BAT8008 is a novel antibody-drug conjugate comprising a TROP-2 antibody and an exatecan payload. Patients...

A pillar of safety: Standardizing oral chemotherapy protocols.

My Linh Vu, David Nowinski, Gilbert Ancira Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23323

e23323 Background: Standardizing protocols for oral chemotherapy treatment and delivery is a critical quality improvement...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page